Novel Anthranilamide-Based FXa Inhibitors: Drug Design, Synthesis and Biological Evaluation
Novel Anthranilamide-Based FXa Inhibitors: Drug Design, Synthesis and Biological Evaluation
About this item
Full title
Author / Creator
Publisher
Switzerland: MDPI AG
Journal title
Language
English
Formats
Publication information
Publisher
Switzerland: MDPI AG
Subjects
More information
Scope and Contents
Contents
Factor Xa (FXa) plays a significant role in the blood coagulation cascade and it has become a promising target for anticoagulation drugs. Three oral direct FXa inhibitors have been approved by the FDA for treating thrombotic diseases. By structure-activity relationship (SAR) analysis upon these FXa inhibitors, a series of novel anthranilamide-based...
Alternative Titles
Full title
Novel Anthranilamide-Based FXa Inhibitors: Drug Design, Synthesis and Biological Evaluation
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_e1d0f3f7a4d14e459e13e45f0959921d
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_e1d0f3f7a4d14e459e13e45f0959921d
Other Identifiers
ISSN
1420-3049
E-ISSN
1420-3049
DOI
10.3390/molecules21040491
